Less Invasive Ventricular Enhancement (LIVE^®)

Vice President and Chief Financial Officer

William R. Abbott has served as our Chief Financial Officer since July 2019. Mr. Abbott has more than thirty years of experience in multi-industry international companies. Prior to joining us, Mr. Abbott was the Senior Vice President and Chief Financial Officer, Treasurer and Secretary of Hancock Jaffe Laboratories, Inc. from 2016 to 2018; where he successfully took the company through an IPO and listing on NASDAQ.  Mr. Abbott was also the Interim President from July 2016 to September 2017. Mr. Abbott served as Vice President of Finance and Corporate Controller and later as Interim Chief Financial Officer of Apollo Medical Holdings, Inc. From 2011 to 2014, he was an independent consultant providing accounting and advisory services. From 2006 to 2011, Mr. Abbott served as Senior Vice President, Chief Financial Officer, Secretary and Treasurer for Cardiogenesis Corporation; where he led a successful sale of the company to CryoLife. From 1997 to 2005, Mr. Abbott served in financial management positions at Newport Corporation, including as Vice President of Finance and Treasurer from 2001 to 2005 and Vice President and Corporate Controller from 1997 to 2001; where he was responsible for 8 aggregate acquisitions for $700M. Prior to that, Mr. Abbott served as Vice President and Corporate Controller of Amcor Sunclipse North America, Director of Financial Planning at Coca-Cola Enterprises, Inc. and Controller of McKesson Water Products Company. Mr. Abbott also spent six years in management positions at PepsiCo, Inc. after beginning his career with PricewaterhouseCoopers, LLP.

Mr. Abbott has a Bachelor of Science degree in accounting from Fairfield University and a Master’s in Business Administration degree from Pepperdine University. 

Chief Operating Officer

Steve Chartier joined BioVentrix in December 2021 as the company’s Chief Operating Officer (COO), bringing with him over 25 years of proven senior leadership experience managing global regulatory strategy, clinical development, and operations for emerging and established medical device and biotechnology companies. Before joining the Company, Mr. Chartier served as Vice President of Global Clinical Affairs at Sirtex Medical Limited, designing and executing clinical studies and clinical operations for a leading manufacturer of target liver cancer therapies. Prior to this time, he served as the CEO and President at Cardiovascular Clinical Sciences Foundation, a prominent CRO providing clinical trial management for cardiovascular studies. Previously, Mr. Chartier served as the Vice President of Regulatory, Quality and Clinical Affairs at Anika Therapeutics directing clinical development and global regulatory channels. Mr. Chartier also served as Chief Operating Officer for Infraredx, Inc. for many years leading the global regulatory, quality, manufacturing and clinical development strategy for a novel cardiac intravascular imaging technology mapping coronary artery disease.

Vice President, US Sales

Mr. Wolff brings over 20 years of experience in sales, strategy, clinical training, and business development in medical device companies specializing in cardiac devices. Most recently, he served as the Senior National Director of Sales for the Medtronic Inc. (MDT) Mechanical Circulatory Support (MCS) business, where he successfully led commercialization efforts for the HeartWare™ HVAD™ System in the U.S. Prior to Medtronic’s $1.1 billion acquisition of the company in 2016, he served in senior sales positions for HeartWare International, Inc. (HTWR) for four years, where he achieved significant revenue growth that was instrumental to the deal.

He earned his bachelor’s degree in exercise and sports management from Colorado State University.